XML 38 R8.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

THE COMPANY AND BASIS OF PRESENTATION | 12 Months Ended
--- | ---
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
THE COMPANY AND BASIS OF PRESENTATION | THE COMPANY AND BASIS OF PRESENTATION Description of Business Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s first commercially approved product in the United States, or U.S., is REZZAYO® (rezafungin for injection) which is indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Melinta Therapeutics, LLC, or Melinta, is commercializing REZZAYO in the U.S. The Company’s proprietary Cloudbreak® platform enables development of novel drug-Fc conjugates, or DFCs, that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. Additional programs are targeting multiple oncology and autoimmune indications. The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe. Basis of Presentation The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At December 31, 2023, the Company had an accumulated deficit of $441.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. At December 31, 2023, the Company had cash and cash equivalents of $35.8 million. Based on the Company’s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company’s obligations for twelve months from the issuance of these financial statements. The Company’s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company’s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company’s business, operating results and financial condition and the Company’s ability to achieve its intended business objectives. Any of these actions could materially harm the Company’s business, results of operations and future prospects. Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s consolidated financial statements relate to estimated collaboration expenses related to the Company’s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company’s collaboration and license agreements. Although the estimates are based on the Company’s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment. Restatement of Consolidated Financial Statements The Company evaluated the indirect taxation consequences upon the first commercial sale of REZZAYO in 2023 and determined that it had a liability for indirect taxation in various tax jurisdictions outside of the U.S. based on its supply chain activities in 2023 and prior years. As a result, it was concluded that in prior years the Company did not appropriately account for indirect taxes which led to understatements of accrued liabilities and operating expenses during the impacted periods. The Company recorded an accrued liability for indirect taxes, and the related interest and penalties, of $11.5 million, an increase in operating expenses of $3.9 million, and an increase in beginning accumulated deficit of $7.6 million, for 2022. The Company recorded an accrued liability for indirect taxes, and the related interest and penalties, of $7.6 million, an increase in operating expenses of $3.7 million, and an increase in beginning accumulated deficit of $3.9 million, for 2021. The consolidated financial statements (as restated) also include adjustments to correct certain other previously identified misstatements relating to fiscal year 2022 and the quarters within 2023 that the Company had determined to be immaterial, both individually and in the aggregate. Impact of Restatement See below for reconciliation from the previously reported amounts to the restated amounts in the consolidated balance sheet, consolidated statement of operations and comprehensive loss, consolidated statement of convertible preferred stock and stockholders’ equity (deficit), and consolidated statement of cash flows as of and for the year ended December 31, 2022. The previously reported amounts were derived from the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 23, 2023. These amounts are labeled as "As Previously Reported" in the tables below. The amounts labeled "Restatement Adjustment" represent the effects of this restatement described above. The following presents a reconciliation of the impacted financial statement line items as previously reported to the restated amounts as of and for the year ended December 31, 2022 (in thousands, except share and per share data):
| Year Ended December 31, 2022
Corrected Consolidated Balance Sheet | As Previously Reported |  | Restatement Adjustment |  | As Restated
Operating lease right-of-use asset | $ | 1,205 |  |  | $ | (106) |  |  | $ | 1,099 |
Total assets | 47,593 |  |  | (106) |  |  | 47,487 |
Accrued indirect tax liabilities | — |  |  | 11,534 |  |  | 11,534 |
Current portion of operating lease liability | 1,317 |  |  | (106) |  |  | 1,211 |
Total current liabilities | 29,972 |  |  | 11,428 |  |  | 41,400 |
Total liabilities | 50,497 |  |  | 11,428 |  |  | 61,925 |
Accumulated deficit | (406,966) |  |  | (11,534) |  |  | (418,500) |
Total stockholders’ deficit | (2,904) |  |  | (11,534) |  |  | (14,438) |
Total liabilities and stockholders’ deficit | 47,593 |  |  | (106) |  |  | 47,487 |
| Year Ended December 31, 2022
Corrected Consolidated Statement of Operations and Comprehensive Loss | As Previously Reported |  | Restatement Adjustment |  | As Restated
Collaboration revenue | $ | 64,288 |  |  | $ | 160 |  |  | $ | 64,448 |
Total revenues | 64,288 |  |  | 160 |  |  | 64,448 |
Research and development | 75,520 |  |  | 1,885 |  |  | 77,405 |
Selling, general and administrative | 18,486 |  |  | 2,060 |  |  | 20,546 |
Total operating expenses | 94,006 |  |  | 3,945 |  |  | 97,951 |
Loss from operations | (29,718) |  |  | (3,785) |  |  | (33,503) |
Loss before income tax expense | (29,527) |  |  | (3,785) |  |  | (33,312) |
Net loss and comprehensive loss | (29,799) |  |  | (3,785) |  |  | (33,584) |
Basic and diluted net loss per common share | (0.43) |  |  |  |  | (0.48) |
Shares used to compute basic and diluted net loss per common share | 69,857,698 |  |  |  |  | 69,857,698 |
| Additional Paid-In Capital
Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders’ Equity (Deficit) | As Previously Reported |  | Restatement Adjustment |  | As Restated
Balance, December 31, 2021 | $ | 398,733 |  |  | $ | (720) |  |  | $ | 398,013 |
Issuance costs for underwritten public offering | (720) |  |  | 720 |  |  | — |
Balance, December 31, 2022 | 404,055 |  |  | — |  |  | 404,055 |
| Accumulated Deficit
| As Previously Reported |  | Restatement Adjustment |  | As Restated
Balance, December 31, 2021 | $ | (377,167) |  |  | $ | (7,749) |  |  | $ | (384,916) |
Net loss | (29,799) |  |  | (3,785) |  |  | (33,584) |
Balance, December 31, 2022 | (406,966) |  |  | (11,534) |  |  | (418,500) |
| Total Stockholders’ Equity (Deficit)
| As Previously Reported |  | Restatement Adjustment |  | As Restated
Balance, December 31, 2021 | $ | 21,573 |  |  | $ | (8,469) |  |  | $ | 13,104 |
Issuance costs for underwritten public offering | (720) |  |  | 720 |  |  | — |
Net loss | (29,799) |  |  | (3,785) |  |  | (33,584) |
Balance, December 31, 2022 | (2,904) |  |  | (11,534) |  |  | (14,438) |
| Year Ended December 31, 2022
Corrected Consolidated Statement of Cash Flows | As Previously Reported |  | Restatement Adjustment |  | As Restated
Operating activities: |  |  |  |  |
Net loss | $ | (29,799) |  |  | $ | (3,785) |  |  | $ | (33,584) |
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |
Non-cash operating lease expense | 1,082 |  |  | (101) |  |  | 981 |
Changes in assets and liabilities: |  |  |  |  |
Accrued indirect tax liabilities | — |  |  | 3,945 |  |  | 3,945 |
Contract liabilities | 2,806 |  |  | (160) |  |  | 2,646 |
Operating lease liabilities | (1,153) |  |  | 101 |  |  | (1,052) |
The remainder of the notes to the Company’s consolidated financial statements have been updated and restated, as applicable, to reflect the impacts from the restatement discussed above.

X
- Definition The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContent Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details
Name: | us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration